Compare PLSE & IRTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PLSE | IRTC |
|---|---|---|
| Founded | 2014 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.6B | 4.2B |
| IPO Year | 2015 | 2016 |
| Metric | PLSE | IRTC |
|---|---|---|
| Price | $52.96 | $120.33 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 13 |
| Target Price | $22.00 | ★ $197.92 |
| AVG Volume (30 Days) | ★ 491.4K | 485.8K |
| Earning Date | 05-07-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 61.71 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $747,138,000.00 |
| Revenue This Year | $840.00 | $19.60 |
| Revenue Next Year | $287.54 | $15.94 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 26.24 |
| 52 Week Low | $12.56 | $100.85 |
| 52 Week High | $55.37 | $210.01 |
| Indicator | PLSE | IRTC |
|---|---|---|
| Relative Strength Index (RSI) | 67.27 | 48.02 |
| Support Level | $24.27 | $119.48 |
| Resistance Level | N/A | $127.58 |
| Average True Range (ATR) | 3.51 | 4.68 |
| MACD | -0.20 | -0.31 |
| Stochastic Oscillator | 64.41 | 33.60 |
Pulse Biosciences Inc is a novel bioelectric medicine company committed to health innovation using its patented Nano-Pulse Stimulation technology, a revolutionary energy modality that delivers nanosecond-duration pulses of electrical energy, each less than a millionth of a second long, to non-thermally clear targeted cells while sparing adjacent noncellular tissue. NPS technology, also referred to as Nanosecond Pulsed Field Ablation (nsPFA) technology delivers nanosecond pulses of electrical energy to nonthermally clear cells while sparing adjacent noncellular tissue.
iRhythm Holdings Inc is a digital healthcare company that creates trusted solutions that detect, predict, and prevent disease. Its principal business is the design, development, and commercialization of device-based technology to provide ambulatory cardiac monitoring services that it believes allow clinicians to diagnose certain arrhythmias quicker and with greater efficiency than other services that rely on traditional technology. Each Zio System combines an FDA-cleared and CE-marked, wire-free, patch-based, 14-day wearable biosensor that continuously records electrocardiogram (ECG) data with a proprietary, FDA-cleared, CE-marked cloud-based data analytic software to help physicians monitor patients and diagnose arrhythmias.